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A NKT cell repertoire is characterized by the expres-
sion of the V19-J26 invariant TCR  chain (V19
NKT cell). This repertoire, as well as a well-estab-
lished V14-J281 invariant TCR + NKT cell subset
(V14 NKT cell), has been suggested to have impor-
tant roles in the regulation of the immune system and,
thus, is a major therapeutic target. Here, we at-
tempted to find specific antigens for V19 NKT cells.
V19 as well as V14 NKT cells exhibited reactivity
to -galactosyl ceramide (-GalCer). Thus, a series
of monoglycosyl ceramides with an axially oriented
glycosidic linkage between the sugar and ceramide
moiety were synthesized and their antigenicity to
V19 NKT cells was determined by measuring their
immune responses in culture with glycolipids. Com-
prehensive examinations revealed substantial anti-
genic activity for V19 NKT cells by -mannosyl cer-
amide.
Introduction
Natural killer T (NKT) cells are defined as lymphocytes
bearing both the common NK marker NK1.1, a member
of the NKR-P1 gene family, and the TCR-CD3 complex
[1, 2]. The major component of NKT cells bearing the
invariant Vα14-Jα18 TCR α chain (Vα14 NKT cells) [3,
4] is positively selected by the nonpolymorphic MHC
class-I-like CD1d molecule in association with β2-
microglobulin (β2m) [5–9]. Vα14 NKT cells are shown to
be reactive to certain glycosphingolipids (GSLs) such
as α-galactosyl ceramide (α-GalCer) in the context of
CD1d [10]. An important feature of NKT cells is their
ability to secrete both proinflammatory (Th1) cytokines
such as IFN-γ and antiinflammatory (Th2) cytokines
such as IL-4 and IL-10 upon stimulation through the
invariant TCR [11–14], suggesting a pivotal role in im-
munoregulatory functions including tumor immunity
[15, 16].
Recently, we demonstrated the presence of a novel
NKT cell repertoire (designated the Vα19 NKT cell) that
was characterized by the expression of the Vα19-Jα26
(AV19-AJ33) invariant TCR α chain [17]. This invariant
TCR was previously found in the peripheral blood of
human, bovine, and mouse deficient in transporter
associated with antigen-processing (Tap)-1 by PCR-*Correspondence: michio@libra.ls.m-kagaku.co.jpbased techniques [18]. Positive selection of the invari-
ant Vα19-Jα26 TCR-bearing cells by the nonclassical
MHC class I molecule MR1 has also been shown [19].
Similar to Vα14 NKT cells, the cells of this repertoire
also produce large amounts of immunoregulatory cyto-
kines in response to the engagement of the invariant
TCR and are considered to have important roles in the
regulation of the immune system (M. Shimamura et al.,
submitted). In addition, they are suggested to partici-
pate in the control of IgA production in intestine [19].
Thus, the search for specific antigens for Vα19NKT
cells is of extreme importance in developing new thera-
pies for immunoregulatory disorders utilizing the func-
tion of the repertoire.
GSLs are one of the principal components in mam-
malian cell membranes [20, 21]. Most glycosphingoli-
pids share a common β-linked glucosyl or galacto-
syl ceramide as a skeletal structure. A discovery of
α-GalCer from marine sponges [22], which is stimulus
to the mammalian immune system by specifically acti-
vating Vα14 NKT cells, prompted us to investigate un-
natural GSLs as agents for stimulating Vα19 NKT cells.
In the current study, we focused on GSLs related to
α-GalCer as potential stimulants for Vα19 NKT cells be-
cause Vα19 as well as Vα14 NKT cells are suggested
to recognize antigens presented by nonclassical MHC
class I molecules, presumably MR1. Therefore, an effi-
cient method of producing α-GalCer-related GSLs was
addressed. We synthesized GSLs by coupling an acti-
vated monosaccharide with a sphingosine precursor
whose amino functionality was masked with an azide
group. The present method enabled us to efficiently ob-
tain a series of naturally occurring and related GSLs.
As a result of comprehensive examinations, immuno-




Several approaches have been reported for the synthe-
sis of azidosphingosine, which is particularly useful as
a glycosylation acceptor [23–28]. However, these meth-
ods are relatively time consuming and technically diffi-
cult. Here, a means of producing azidosphingosine with
fewer steps and easier operations was established
(Figure 1). Herold reported an efficient method of syn-
thesizing sphingosine [29] starting with Garner’s alde-
hyde 1 [30] as a precurser. Addition of 1-pentadecynyl-
lithium to 1 afforded amino alcohol 2 in 72% yield as a
mixture of diastereomers. The ratio of diastereomers
was determined by 1H NMR spectroscopy (51% yield
for the anti product). Although these isomers could be
separated at this point by repeating the chromato-
graphic purification, it was easier to separate them af-
ter protection of the hydroxyl group with benzyl ether
in the case of large-scale preparation. After the 3-OH
group had been protected by the benzylation, a desired
anti isomer of 2 was exposed to HCl-MeOH to give 3.
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Reagents and conditions. (A) 1-pentadecyne, n-butyllithium, hexamethylphosphoramide (HMPA), THF, −78°C, 72%. (B) NaH, BnBr, DMF, 0°C
to rt. (C) 5% HCl/MeOH, 0°C to rt. (D) TfN3, NaOMe, DMAP, MeOH, room temperature, 81% yield from 2.The amino alcohol 3 was then treated with TfN3 (0.4 M w
ein CH2Cl2) [31, 32], NaOMe, and DMAP in MeOH at
room temperature to afford compound 4 in 81% yield
2from anti-2. As a result, the sphingosine building block
4 was prepared in 4 steps starting from Garner’s alde- O
shyde 1 in an overall yield of 40%.
Next, the appropriate glycosyl donors to be coupled a
1with 4 were considered. We decided to use 2-O-ben-
zylated glycosyl donors for coupling a monosaccha- d
srides with a 2-OH group and 2-azido-sugars for cou-
pling glucosamine or galactosamine to preferentially m
bobtain α-glycosides while taking into account the an-
omeric effect. To select these protective groups was t
tadvantageous to the simple deprotection of the final
products. The thioether was chosen as a selective pro- a
tecting group for the anomeric center.
The glycosylation of neutral sugars (glucose, galac- f
1tose, mannose, xylose, fucose, talose, and altrose) with
4 was carried out by using DMTST (Dimethyl(methylthio) a
2sulfonium trifluoromethane sulfonate) (Table 1). The α
and β glycosides were separated by chromatography yield from 12α.
Table 1. Synthesis of Neutral Sugar-Based α-Glycosyl Ceramides
Reagents and conditions. (A) DMTST, MS 4 Å, CH2Cl2, 0°C to room temperature. (B) H2, Pd-CaCO3, stearic anhydride, AcOEt, room
temperature. (C) H2, Pd(OH)2, MeOH/AcOEt (2/1), room temperature.
aAfter deacetylation with NaOMe/MeOH.
bAt this step, α and β anomers could not be separated. These anomers were separated after peracetylation of altrosylceramide. The ratio of
anomers was determined by 1H NMR of peracetylated altrosylceramide.
cYield for a mixture of anomers.ith a silica-gel column eluted with n-hexane-ethyl ac-
tate.
In the case of glucosyl and xylosyl donor, 6-O-acetyl-
, 3, 4-tri-O-benzyl thioglucoside 5 and 3-O-acetyl-2,4-
-dibenzyl thioxyloside 8 were selected because in-
eparable glycosylation products were obtained when
perbenzylated donor was used. The azide group in
2–18 was converted to a stearoyl amide group by hy-
rogenation with Lindlar’s catalyst in the presence of
tearic anhydride followed by hydrogenation with Perl-
ann’s catalyst to afford the desired neutral-sugar-
ased GLSs (19–25) in good yield (Table 1). Although
he altrosylceramide 25 obtained at this step was a mix-
ure of anomers, the components were easily separable
fter peracetylation.
Glucuronic acid containing glycolipid was prepared
rom 12α (Figure 2). After transformation of the azide in
2α to a stearoyl amide group, Jones oxidation of the
lcohol in 26 afforded carboxylic acid, which afforded
7 upon hydrogenation with Pearlman’s catalyst in 69%
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679Figure 2. Synthesis of α-Glycosylceramide
Containing Glucuronic Acid
Reagents and conditions. (A) H2, Pd-CaCO3,
stearic anhydride, AcOEt, rt. (B) Jones rea-
gent, acetone, 60°C. (C) H2, Pd(OH)2, MeO-
H:AcOEt=2:1, rt, 69% yield from 12.For the sialylation of 4 (Figure 3), thiophenyl sialoside
28a showed no reactivity to 4 with DMTST or NIS-TfOH
as a promoter probably because of the bulkiness of the
anomeric position being a quarternally carbon center
and the weak nucleophilicity of the thiophenyl group.
Hence, a less bulky and more nucleophilic ethyl thiosi-
aloside was selected as a donor. Using NIS-TfOH but
not DMTST for coupling, this donor gave the sialoside
29b in a dramatically improved yield in a shorter reac-
tion time. The glycosylation reaction was completed
within 2 hr, judging from a TLC analysis (n-hexane-ethyl
acetate), and the combined yield of α and β anomers
was 84% (α/β = 2.3/1). The desired β-sialoside 29b-β
was converted to sialylceramide 32 in 3 steps with 82%
yield (amide formation using hydrogenation with Lind-
lar’s catalyst in the presence of stearic anhydride fol-
lowed by hydrolysis of acetyl and methyl ester with
lithium hydroxide and hydrogenation with Pearlman’s
catalyst).
Selective manipulation of 2-amino group in the sugar
residue and the 2-amide group in the sphingosine moi-
ety is required to synthesize glycosamynyl and galacto-
saminyl ceramide via the glycosylation of 4. Because
of the difficulty in controlling the reactivity of these two
functional groups, we chose ceramide 33 as a glycosyl
acceptor in this particular case. Glycosyl imidates were
chosen as more reactive glycosyl donors in order to
compensate for the weak nucleophilicity of the accep-
tor. As a result (Figure 4), a glycoside 35 was obtained
in 48% yield as a mixture of anomers upon the reaction
of 33 and 34 with TESOTf as a promoter. Each isomer
was separated by silica-gel column chromatography.
The coupling of 36 and 33 afforded 37 in 29% yield with
BF3 , Et2O as a promoter. In this case, α-anomer was
formed as the sole product. 35α and 37 were hydroge-
nated with Pearlman’s catalyst in the presence of 0.1 ity (Figure 5A). Vα19 Tg TCRα but not C57BL/6 cells
Figure 3. Synthesis of β-Sialyl Ceramide
Reagents and conditions. (A) NIS, TfOH, MS
4 Å, CH2Cl2:(CH2Cl)2=2:1, −40°C to −30°C.
(B) H2, Pd-CaCO3, stearic, anhydride, AcOEt,
rt. (C) LiOH, MeOH:H2O=4:1, 0°C to rt. (D) H2,
Pd(OH)2, MeOH, rt, 82% yield from 29b-.N aqueous HCl to afford 38 and 39 in a quantitative
yield, respectively.
Immunological Activities of the Synthesized GSLs
Alpha-GalCer, a specific activator for Vα14 NKT cells,
was tested for its potential to activate Vα19 NKT cells
in a continuous search for specific antigens for this
novel NKT cell repertoire. Total MNCs were prepared
from livers of invariant Vα19-Jα26 transgenic (Tg)+
TCRα−/− as well as C57BL/6 and β2m−/− mice for the
determination of the biological activity of GSLs. They
were used as responders without further fractionation
because (1) only Vα19 Tg+ cells are generated as TCR+
cells in Vα19 Tg+ TCR α−/− mice, (2) the liver is the organ
with the largest proportion of NKT cells among MNCs
(Vα19 Tg+ NK1.1+ cells are about 30%), and (3) liver
MNCs include populations of dendritic cells, macro-
phages, and B cells, which have the potential to func-
tion as antigen-presenting cells (APCs). The liver MNCs
were cultured in the presence of α-GalCer, and the im-
mune responses were monitored by measuring cyto-
kine secretion in the culture fluid and cell proliferation
(Figure 5A). Similar to C57BL/6 cells, Vα19 Tg+ cells
seemed to have some responsiveness to α-GalCer. In
contrast, both C57BL/6 and Vα19 Tg+ cells showed no
detectable responsiveness to β-GalCer. Vα19 NKT cells
are the sole component of the NKT cell population in
Vα19 Tg+ TCRα−/− mice, whereas Vα14 NKT cells are
the major subset in C57BL/6 mice. Therefore, these
findings strongly suggest that Vα19 NKT cells as well
as Vα14 NKT cells [10] recognize α-glycosylated cer-
amides.
To test this hypothesis, we synthesized a series of
α-glycosyl ceramides with a naturally occurring mono-
saccharide residue and examined their antigenic activ-
+ −/−
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680Figure 4. Synthesis of α-Glucosaminyl and
α-Galactosaminyl Ceramides
For the synthesis of glucosaminyl and galac-
tosaminyl ceramides, 2-azide-glycosyl do-
nors (34, 36) were used. They were coupled
with 3-O-benzyl ceramide. deprotection of
the benzyl groups and conversion of the
azide to the amino group in the adducts (35,
37) were performed in a successive pro-
cedure to afford the final products (38, 39).were most efficiently induced to proliferate and pro- r
tduce IL-4 and IFN-γ by α-ManCer rather than α-GalCer.
In contrast, C57BL/6 cells were responsive to α-GalCer s
cand, to a certain extent, to α-glucosyl and glucuronyl
ceramide (α-GlcCer and α-GlcUACer). Thus, these re-
bsults suggest that Vα19 NKT cells recognize α-ManCer
as a specific antigen in contrast to Vα14 NKT cells re- c
sactive to α-GalCer [10], α-GlcCer [10], and α-GlcUACer
[33, 34]. Few NKT cells are generated in β2m−/− mice d
tbecause the expression of β2m associated with non-
classical MHC class I molecules is required for the pos- e
Nitive selection of these NKT cell repertoires. Less reac-
tivity by β2m−/− cells to α-ManCer further supports that b
cthe immune responses to α-ManCer were conferred to
Vα19 NKT cells in Vα19 Tg+ TCRα−/− mice. e
wThe biological activity of α-ManCer toward Vα19 NKT
cells is not apparently so significant compared with the s
ractivity of α-GalCer on Vα14 NKT cells. Thus, we per-
formed a Student’s t test to examine whether the im-
cmune responses of Vα19 Tg cells to α-ManCer were
statistically significant. The results of the test indicated A
othat the biological activity of α-ManCer to Vα19 Tg cells
was more significant than the activity of controls α
g(α-fucosyl ceramide [FucCer] or β-GalCer) with prob-
ability more than 96% (the α values were less than r
i0.04).
The immune responsiveness of Vα19 Tg cells to g
gα-ManCer was dependent on the dose of the glycolipid.
Vα19Tg cells but not C57BL/6 or β2m−/− cells re- i
rsponded to α-Mancer in a dose-dependent manner
(Figure 5B). The immune responses reached a maxi- g
Nmum with the concentration of α-ManCer more than
2 g/ml, whereas α-FucCer did not induce any immune (esponses of Vα19 Tg cells even with such concentra-
ion. These observations further support that α-ManCer
pecifically induces immune responses of Vα19 NKT
ells.
MR1-dependent development of invariant Vα19 TCR-
earing cells has been reported [19]. This report well
orresponds to the present result that immune re-
ponses of Vα19 Tg cells to α-ManCer are β2m depen-
ent. Vα19 Tg cells were stimulated with MR1 transfec-
ants, and the immune responses were determined to
xamine whether the immune responsiveness of Vα19
KT cells are MR1 dependent (Figure 6). Vα19 Tg cells
ut not C57BL/6 or β2m−/− cells were activated during
oculture with MR1 transfectants. This activation was
nhanced when the MR1 transfectants were loaded
ith α-ManCer before coculture. Thus, it is strongly
uggested that invariant Vα19 TCR+ cells recognize and
espond to α-ManCer presented by MR1.
We next focused on the antigenicity of α-glycosyl
eramides with an α-mannosyl-related sugar moiety.
ssuming the importance of the 2-axial hydroxy group
f the α-mannosyl residue, we tested for activity of
-altrosyl ceramide and α-talosyl ceramide (the 3-hydroxy
roup in α-altrose and 4-hydroxy group in α-talose are
eversed from those in α-mannose). However, no signif-
cant immune responses of Vα19 NKT cells to these
lycolipids were found (Figure 5A), suggesting a strin-
ent recognition of the α-mannosyl residue by the
nvariant Vα19-Jα26 TCR. Because the natural occur-
ence of α-ManCer has not been reported yet, this
lycolipid possibly mimics natural ligands for the
KT cells. We have recently found that 2,6-α-Man
α-Man)- and 6-α-Man-β-GlcNH -phosphatidylinositol2
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681Figure 5. Activation of Vα19 Tg+ Cells with
Glycolipid Antigens in Culture
(A) Liver MNCs prepared from Vα19 Tg+
TCRα−/−, C57BL/6, and β2m−/− mice were
cultured in the presence (1 g/ml) or ab-
sence of glycolipids. After 2 days, the im-
mune responses were monitored by mea-
suring cell proliferation ([3H]-thymidine incor-
poration for 5 hr) and IL-4 and IFN-γ secretion
in the culture supernatants. Results are
shown as the fold increase relative to the
control cultures with vehicle (1/200 v/v
DMSO). The error bars indicate the standard
deviations. Abbreviations: α-Gly, α-glycosyl
ceramide; β-Gal, β-galactosyl ceramide; Sia,
D-N-acetyl neuraminyl; Tal, D-talosyl; and Alt,
D-altrosyl.
(B) Dose-dependent activation of Vα19 Tg+
cells with α-ManCer in culture. Liver MNCs
prepared from Vα19 Tg+ TCRα−/−, C57BL/6,
and β2m−/− mice were cultured in the pres-
ence of the indicated dose of glycolipids.
After 2 days, the immune responses were
monitored by measuring cytokine secretion
into the culture supernatants. One of two in-
dependent experiments giving similar results
is demonstrated.have a similar degree of antigenicity to Vα19 NKT cells as
α-ManCer (M. Shimamura et al., submitted). These ob-
servations suggest the importance of the α-mannosyl
residue in an appropriate location for the recognition
by the invariant Vα19-Jα26 TCR when the antigenic gly-
colipid is presented by MR1. It is possible that glycolip-
ids with nonreducing end α-mannosyl residue(s) occur
in mammalian cells that are more immunocompetent
toward Vα19 NKT cells than the glycolipids so far char-
acterized. Another possibility is that modification of thelipid structure in α-mannosylated glycolipids will alter
the interaction with MR1 and improve the recognition
of the α-mannose residue by the invariant TCR.
Significance
In this study, we accomplished the efficient chemical
synthesis of a series of GSLs with azide sphingosine
as a glycosyl acceptor. The methods we used will


















SFigure 6. Stimulation of Vα19 Tg+ Cells with α-ManCer in the
Context of MR1 M
1MR1-transfected or nontransfected Raji cells were incubated with
mα-ManCer (2 g/ml) or vehicle for 18 hr. They were irradiated (3,000
DR), washed with medium, and then cultured with liver MNCs iso-
wlated from Vα19 Tg+ TCRα−/−, C57BL/6, or β2m−/− mice for 2 days.
DCytokine production in the culture fluid was determined by ELISA.
iThe error bars indicate the standard deviations. Experiments were
crepeated twice, and similar results were obtained.A
The biological data on the GSLs demonstrate that L
a-ManCer is a potent stimulant for V19 NKT cells.
oThe present study serves as the second example of
cthe recognition of GSLs in the context of nonpolymor-
iphic MHC class-I-like molecules by invariant TCRs.
pSuch an immune recognition system, namely the spe- i
cific recognition of -ManCer with MR1 or -GalCer h
with CD1 by the invariant V19 or V14 TCR, may be
Sof fundamental importance for the regulation of the
immune system presumably by linking the natural S





Outlines of the methods used to synthesize GSLs are shown in
T
Table 1 and the Supplemental Data available with this article online.
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RC57BL/6 mice were purchased from Sankyo Service (Tokyo). Re-
Acombination activating gene (Rag)-2-deficient mice and β2m-defi-
Pcient mice were obtained from Jackson Laboratory (Bar Harbor,
Maine). TCR Cα-deficient mice with the C57BL/6 background [35]
Rwere provided by Drs. H. Ishikawa (Keio University) and M. Nanno
(Yakult Co.). All experiments on mice were performed in accor-
dance with the guidelines of Mitsubishi Kagaku Institute of Life Sci-
ences.
Establishment of V19 Transgenic Mice
A Vα19-Jα26 (AV19-AJ33) transgene with the endogenous TCR α
promoter and the enhancer was injected into TCR Cα-deficient fer-
tilized eggs, and transgenic (Tg) mouse lines were established (M.
Shimamura et al., submitted).
Cell Preparations
Mononuclear cells (MNCs) were prepared from single-cell suspen-
sion of mouse organs by density gradient centrifugation with Lym-
phosepar II (IBL, Gunma, Japan; d = 1.090) for spleen and bonearrow and Percoll (Pharmacia, Uppsala, Sweden) for liver-cell
reparations as described previously [17].
R1 Transfectants
ouse MR1 A cDNA [36] was amplified from C57BL/6 spleen cells
ith the following PCR primers: 5#-MR1, 5#-ATGATGCTCCTGGT
ACCTGG-3#; FLAG-3#-MR1, 5#-CTACTTGTCATCGTCATCCTTGTA
TC(FLAG)-AGAGGGAGAGCTTCCCTCAT-3#.
MR1 transfectants were established as described elsewhere (M.
himamura et al., submitted). Briefly, the cloned PCR product was
ecombined into a eukaryotic expression vector, (pCXN) [37] (pro-
ided by Dr. J. Miyazaki, Osaka University), and the expression vec-
or was transfected into a human Burkitt’s B lymphoma, Raji [38]
obtained from ATCC). The transfectants were selected in the cul-
ure medium containing G418 (1 mg/ml) for 1 month. The expres-
ion of FLAG (Asp-Tyr-Lys-Asp-Asp-Asp)-MR1 in the transfectants
as analyzed by Western blot with anti-FLAG antibody and HRP-
abeled anti-mouse immunoglobulin (Sigma, St. Lewis).
timulation of V19 Tg+ Cells with MR1 Transfectants
R1-transfectants or their parental cells (1 × 105 per well in DMEM,
0% FCS) were irradiated (3,000 R). They were incubated in the
edium with glycolipids (2 g/ml) for 18 hr and washed twice with
MEM. These cells were cocultured with liver MNCs (1 × 106 per
ell) from Vα19 Tg or non-Tg mice (2–4 months of age) in 200 l
MEM (10% FCS) for 2 days. Immune responses by the liver MNCs
n the mixed lymphocyte reactions were monitored by measuring
ytokines in the culture fluid.
ntigen Assay
iver MNCs (106) from indicated mouse strains (2 to 4 months of
ge) were cultured in 200 l of DMEM (10% FCS) in the presence
f glycolipids (1 g/ml). In some experiments, concentration of gly-
olipids in culture was serially altered. Concentration of cytokines
n the supernatants was determined by ELISA after 2 days. Cell
roliferation was assessed at day 2 of culture by measuring the
ncorporation of [3H]-thymidine (0.5 Ci/ml, Amersham, Bucking-
amshire, United Kingdom) for 5 hr.
upplemental Data
upplemental Data include Supplemental Experimental Procedures
nd can be found with this article online at http://www.chembiol.
om/cgi/content/full/12/6/677/DC1/.
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